MedTrace Logo

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

NCT01018186 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 503

Last updated 2018-02-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444

Conditions

Interventions

DRUG

Fluticasone Furoate/GW642444

Combination inhaled corticosteroid and long-acting beta2-agonist

DRUG

Fluticasone propionate

Inhaled corticosteroid

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-19
Primary Completion
2011-05-01
Completion
2011-05-12

Countries

  • United States
  • Germany
  • Thailand
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018186 on ClinicalTrials.gov